BUZZ-Korro Bio plunges on trial failure, Novo Nordisk deal halt

Reuters

Nov 13, 2025

BUZZ-<a href="https://laohu8.com/S/KRRO">Korro Bio</a> plunges on trial failure, <a href="https://laohu8.com/S/NVO">Novo Nordisk</a> deal halt

** Shares of drug developer Korro Bio KRRO.O plunge 76.1% to $7.62 in extended trading

** KRRO says its experimental drug KRRO-110 for a rare lung and liver disease produced a key protein in patients but failed to reach expected levels

** The drug was being tested in Alpha-1 Antitrypsin Deficiency, a rare inherited disorder that can cause severe lung and liver disease

** Co also pauses its licensing deal with Novo Nordisk NOVOb.CO for 12 months, effective November 11

** Co says the collaboration may yield no benefits, prompting Korro Bio to wind down its related R&D activities immediately

** KRRO says Novo Nordisk will reimburse Korro for certain wind-down costs; additionally, Korro announced a 34% workforce reduction

** KRRO stock down 17.5% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583581936"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583581936\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583581936?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 06:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583581936","market":"us","top_or_hot":-1,"title":"BUZZ-Korro Bio plunges on trial failure, Novo Nordisk deal halt","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> plunges on trial failure, <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> deal halt</title></head><body><p>** Shares of drug developer Korro Bio <span>KRRO.O</span> plunge 76.1% to $7.62 in extended trading</p><p>** KRRO says its experimental drug KRRO-110 for a rare lung and liver disease produced a key protein in patients but failed to reach expected levels</p><p>** The drug was being tested in Alpha-1 Antitrypsin Deficiency, a rare inherited disorder that can cause severe lung and liver disease</p><p>** Co also pauses its licensing deal with Novo Nordisk <span>NOVOb.CO</span> for 12 months, effective November 11</p><p>** Co says the collaboration may yield no benefits, prompting Korro Bio to wind down its related R&amp;D activities immediately</p><p>** KRRO says Novo Nordisk will reimburse Korro for certain wind-down costs; additionally, Korro announced a 34% workforce reduction</p><p>** KRRO stock down 17.5% YTD </p><p>(Reporting by Padmanabhan Ananthan)</p><p>((Padmanabhan.Ananthan@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Korro Bio plunges on trial failure, Novo Nordisk deal halt</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Korro Bio plunges on trial failure, Novo Nordisk deal halt\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 06:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> plunges on trial failure, <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> deal halt</title></head><body><p>** Shares of drug developer Korro Bio <span>KRRO.O</span> plunge 76.1% to $7.62 in extended trading</p><p>** KRRO says its experimental drug KRRO-110 for a rare lung and liver disease produced a key protein in patients but failed to reach expected levels</p><p>** The drug was being tested in Alpha-1 Antitrypsin Deficiency, a rare inherited disorder that can cause severe lung and liver disease</p><p>** Co also pauses its licensing deal with Novo Nordisk <span>NOVOb.CO</span> for 12 months, effective November 11</p><p>** Co says the collaboration may yield no benefits, prompting Korro Bio to wind down its related R&amp;D activities immediately</p><p>** KRRO says Novo Nordisk will reimburse Korro for certain wind-down costs; additionally, Korro announced a 34% workforce reduction</p><p>** KRRO stock down 17.5% YTD </p><p>(Reporting by Padmanabhan Ananthan)</p><p>((Padmanabhan.Ananthan@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL6N3WO14G:1","article_id":"2583581936","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583581936","pubTimestamp":1762988173,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Korro Bio plunges on trial failure, Novo Nordisk deal halt** Shares of drug developer Korro Bio KRRO.O plunge 76.1% to $7.62 in extended trading** KRRO says its experimental drug KRRO-110 for a r","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KRRO":"Korro Bio, Inc."},"translate_title":"BUZZ-Korro Bio因试验失败、诺和诺德交易停止而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRRO":0.9},"content_text":"BUZZ-Korro Bio plunges on trial failure, Novo Nordisk deal halt** Shares of drug developer Korro Bio KRRO.O plunge 76.1% to $7.62 in extended trading** KRRO says its experimental drug KRRO-110 for a rare lung and liver disease produced a key protein in patients but failed to reach expected levels** The drug was being tested in Alpha-1 Antitrypsin Deficiency, a rare inherited disorder that can cause severe lung and liver disease** Co also pauses its licensing deal with Novo Nordisk NOVOb.CO for 12 months, effective November 11** Co says the collaboration may yield no benefits, prompting Korro Bio to wind down its related R&D activities immediately** KRRO says Novo Nordisk will reimburse Korro for certain wind-down costs; additionally, Korro announced a 34% workforce reduction** KRRO stock down 17.5% YTD (Reporting by Padmanabhan Ananthan)((Padmanabhan.Ananthan@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}